Core Viewpoint - The company, Gilead Sciences-B (01672.HK), will present data on ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria [1] Summary by Relevant Sections Clinical Data Presentation - The presentation will include findings from a 28-day multiple ascending dose study (NCT06680440) of ASC30, highlighting its superior weight loss effects in obese subjects [1] - The abstract title for the discussion is "ASC30, an oral GLP-1R biased small molecule agonist shows superior weight loss effects in obese subjects: a 28-day multiple ascending dose study" [1] Event Details - The discussion will take place on September 16, 2025, from 12:00 to 13:00 (Central European Summer Time) [1] - The report number for this presentation is 827 [1] Company Perspective - Dr. Wu Jinzi, founder, chairman, and CEO of the company, expressed anticipation for showcasing the clinical data at the EASD meeting, believing that the efficacy and safety data will position ASC30 as a differentiated treatment option for obesity [1]
歌礼制药-B(01672.HK)将在第61届欧洲糖尿病研究协会(EASD)年会上报告ASC30口服小分子GLP-1R激动剂28天多剂量递增研究结果